Bindung von Monosacchariden über die Isocyano‐ und Carben‐Funktion an das Metall‐Atom: Chrom(0), Wolfram(0)‐, Rhodium(III)‐, Iridium(III)‐, Palladium(II)‐, Platin(II)‐ und Gold(I)‐Komplexe von 1,3,4,6‐Tetra‐<i>O</i>‐acetyl‐2‐desoxy‐2‐isocyano‐α‐<scp>D</scp>‐glucose und ‐ β‐<scp>D</scp>‐glucose

Pill, Thomas; Polborn, Kurt; Beck, Wolfgang

doi:10.1002/cber.19901230104

Cited by 37 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analogs of cisplatin have been prepared in which the ammine ligands are replaced by aminosugars. Early studies demonstrated that complexes with 2-amino-2-deoxy- d -glucopyranose coordinated to platinum could be prepared but displayed no significant anticancer activity. − Using 2,3-diaminosugars, complexes analogous to oxaliplatin were obtained that exhibited promising activity in vitro and in animal models. For instance, PtCl 2 (2,3-diamino-2,3-dideoxy- d -glucose) (Chart A) given as a 50 mg kg –1 intraperitoneal injection was able to more than double the survival time of mice bearing a sarcoma 180 .…”

Section: Platinum(ii) Compounds With a Mechanism Of Action Similar To...mentioning

confidence: 99%

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

2016

View full text Add to dashboard Cite

The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer,, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing non-classical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs. The use of nanodelivery devices has also grown and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs. In this review, we discuss these efforts to create the next generation of platinum anticancer drugs. The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished. We then describe approaches that explore non-classical platinum(II) complexes with trans geometry and with a monofunctional coordination mode, polynuclear platinum(II) compounds, platinum(IV) prodrugs, dual-treat agents, and photoactivatable platinum(IV) complexes. Nanodelivery particles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles. Additional nanoformulations including supramolecular self-assembled structures, proteins, peptides, metal-organic frameworks, and coordination polymers will then be described. Finally, the significant clinical progress made by nanoparticle formulations of platinum(II) agents will be reviewed. We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also reflect our optimism that the next generation of platinum cancer drugs is about to arrive.

show abstract